Related Experiment Video

Updated: Jul 19, 2026

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

Expression of tyrosine kinase receptors in malignant midgut carcinoid tumors

Staffan Welin1, Marie Louise Fjällskog, Jan Saras

  • 1Department of Medical Sciences, Unit of Endocrine Oncology, University of Uppsala, Uppsala, Sweden. staffan.welin@medsci.uu.se

Neuroendocrinology
|October 19, 2006
PubMed
Abstract

Insights

Malignant midgut carcinoid tumors express key tyrosine kinase receptors (TKR), including PDGFRalpha, PDGFRbeta, and EGFR. This suggests potential for targeted therapies like TKRI and monoclonal antibodies in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Tyrosine kinase receptors (TKR) play a crucial role in tumor progression and are targets for novel cancer therapies.
  • Midgut carcinoid tumors are a type of neuroendocrine tumor with limited targeted treatment options.
  • Investigating TKR expression in midgut carcinoids can identify potential therapeutic strategies.

Observation:

  • Immunohistochemistry revealed expression of platelet-derived growth factor receptor-alpha (PDGFRalpha), PDGFRbeta, and epidermal growth factor receptor (EGFR) in midgut carcinoid tumor cells.
  • PDGFRbeta (88%) and EGFR (73%) showed high expression in tumor cells.
  • Tumor stroma also expressed PDGFRalpha (35%) and PDGFRbeta (94%).

Findings:

  • Three out of four tested TKRs (PDGFRalpha, PDGFRbeta, EGFR) are expressed in malignant midgut carcinoid tumors.
  • Human neuroendocrine tumor cells demonstrated a functional response to platelet-derived growth factor (PDGF).
  • No c-kit expression was detected in the tumor tissues.

Implications:

  • Malignant midgut carcinoid tumors may be susceptible to treatment with tyrosine kinase receptor inhibitors (TKRI) or monoclonal antibodies.
  • These findings support further exploration of TKRI and antibody-based therapies in clinical trials for midgut carcinoids.
  • Targeting specific TKRs could offer new therapeutic avenues for patients with this rare cancer.

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...